Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Plamotamab
XmAb13676 · 2 trials · 3 indications
Percentage of participants with treatment emergent adverse events (TEAEs) and serious adverse events (SAEs)
| Arm | Type | Description |
|---|---|---|
| Dose Escalation | EXPERIMENTAL | Plamotamab administered SC |
| Non-CLL B Cell Malignancies (Group NHL) Part A | EXPERIMENTAL | XmAb13676 administered IV up to 8 weeks, if receiving benefit, this can be extended at investigator's discretion |
| CLL/SLL (Group CLL) Part A | EXPERIMENTAL | XmAb13676 administered IV up to 8 weeks, if receiving benefit, this can be extended at investigator's discretion |
| Non-CLL B Cell Malignancies (Group NHL) Part B | EXPERIMENTAL | XmAb13676 administered IV up to 8 weeks, if receiving benefit, this can be extended at investigator's discretion |
| CLL/SLL (Group CLL) Part B | EXPERIMENTAL | XmAb13676 administered IV up to 8 weeks, if receiving benefit, this can be extended at investigator's discretion |
| Non-CLL B Cell Malignancies (Group NHL) Part C / Expansion | EXPERIMENTAL | XmAb13676 administered IV up to 8 weeks, if receiving benefit, this can be extended at investigator's discretion |
| Non-CLL B Cell Malignancies (Group NHL) Part D / Expansion | EXPERIMENTAL | XmAb13676 administered SC up to 8 weeks, if receiving benefit, this can be extended at investigator's discretion |
| Name | Type | Description |
|---|---|---|
| Plamotamab | BIOLOGICAL | Biological |
| XmAb13676 | BIOLOGICAL | Biological |
Inclusion Criteria: Adult participants with moderately to severely active RA. * Documented diagnosis of RA and meeting the 2010 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for RA at least 3 months prior to screening * Inadequate respon...
XmAb13676 is an investigational monoclonal antibody being studied for B-cell non-Hodgkin lymphoma, a type of blood cancer. It has also been evaluated in chronic lymphocytic leukemia. XmAb13676 is not yet approved for any indication and remains in clinical development.
XmAb13676 targets CD20, a protein found on the surface of B cells. By binding CD20, the antibody is designed to engage the immune system against CD20-expressing hematologic malignancies, including B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia.
XmAb13676 is being developed by Xencor, Inc., a biopharmaceutical company that trades on the Nasdaq under the ticker symbol XNCR. Xencor is responsible for the clinical program evaluating the antibody in CD20-expressing hematologic malignancies.
XmAb13676 is in Phase 1 clinical development. The Phase 1 study has been completed, and the drug remains investigational. It has not been approved by the FDA or any other regulatory agency for B-cell non-Hodgkin lymphoma or any other indication.
XmAb13676 has been evaluated in one clinical trial, NCT02924402, titled a study to evaluate safety and tolerability of XmAb13676 (plamotamab) in patients with CD20-expressing hematologic malignancies. The Phase 1 trial enrolled 154 patients across the United States, France, South Korea, and the United Kingdom and is now completed.
Yes, XmAb13676 is also known as plamotamab. The two names refer to the same investigational anti-CD20 monoclonal antibody developed by Xencor. The clinical trial NCT02924402 lists both names in its title.